Ampio Pharmaceuticals, Inc. (AMPE): Marketing Mix Analysis [Dec-2025 Updated]

You're looking at a biotech that's pivoted hard. After terminating the lead candidate, OA-201, back in February 2024, the old playbook for Ampio Pharmaceuticals, Inc. is officially closed. Honestly, as an analyst who's seen plenty of these transitions, the late 2025 'marketing mix' isn't about selling drugs; it's about maximizing the remaining cash and intellectual property while the stock trades on the OTC Pink market. We need to look past traditional Product, Place, Promotion, and Price to see what the real strategy is now-asset preservation and clear communication to the remaining shareholders. Dive in below to see how their 4Ps have been completely redefined for this wind-down phase.

Ampio Pharmaceuticals, Inc. (AMPE) - Marketing Mix: Product

You're looking at the product strategy for Ampio Pharmaceuticals, Inc. as of late 2025, which, honestly, is a story about the wind-down of a development pipeline, not a typical product launch cycle.

The company's most recent major development effort, the lead candidate OA-201 program, which was aimed at treating osteoarthritis of the knee (OAK), was officially terminated in February 2024. This decision followed data from a set of non-clinical studies where the expected pain reduction benefit was simply not observed. That failure meant the company's plans to file for an Investigational New Drug (IND) application were abandoned.

As a pre-revenue stage biopharmaceutical company, Ampio Pharmaceuticals has no commercially approved drugs currently generating revenue. To put this in historical context, the last reported Annual Revenue, as of December 31, 2014, was $76.8K. The company's operational status shifted significantly following the OA-201 termination and subsequent stockholder vote.

The core product offering, in the context of a company winding down operations, is now defined by its remaining intellectual property (IP) and the cash reserves held to manage that wind-down. The Plan of Dissolution was approved by stockholders on August 15, 2024, and the company was formally dissolved as of August 16, 2024. The goal became maximizing the cash position to fund an orderly wind down.

The remaining assets that constitute this core 'product' are the intellectual property associated with preclinical candidates. Here's a quick look at what remains in the development portfolio, even as the company dissolves:

Regarding the cash component, which is a critical part of the current 'product' for stockholders, the latest reported liquidity position before the dissolution process began showed $12.7 million of cash and cash equivalents as of December 31, 2022. Any distribution of remaining cash to stockholders is subject to the settlement of legal obligations and approval by the Delaware Chancery Court.

The company's focus on its remaining IP is centered on protecting these assets through patents and trade secrets, though the ability to fund further development is limited by the dissolution plan.

• Terminated lead candidate: OA-201.
• OA-201 termination date: February 2024.
• Last reported revenue date: December 31, 2014.
• Dissolution effective date: August 16, 2024.
• Preclinical asset AR-300 indication: Pain.
• Preclinical asset NCE-001 indication: Alzheimer Disease.

Finance: draft final cash reconciliation statement by next Tuesday.

Ampio Pharmaceuticals, Inc. (AMPE) - Marketing Mix: Place

You're looking at the distribution footprint for Ampio Pharmaceuticals, Inc. as of late 2025, and the picture is one of winding down, not scaling up. The core strategy for Place, or bringing the product to market, is effectively non-existent because the company has formally ceased operations.

No commercial distribution network for pharmaceutical sales exists in late 2025. The Plan of Dissolution, recommended by the board, was approved by stockholders on August 15, 2024. Consequently, Ampio Pharmaceuticals, Inc. dissolved as of August 16, 2024, as per the Certificate of Dissolution. This action directly negates any current or near-term commercial distribution strategy for products like the terminated OA-201 program.

Corporate operations are centralized in Englewood, Colorado, USA. The corporate office address is listed as 9800 Mount Pyramid Court, Suite 400, Englewood, CO 80112, United States. This centralization reflects a minimal operational footprint, which is consistent with the company's status.

Research and clinical activities were primarily conducted in the United States. Historically, clinical studies, such as the STRIDE study, were conducted across 14 sites in the USA. The company's focus was on the development of therapies within the United States.

Stock trading shifted to the OTC Pink market (OTC: AMPE) following delisting. Ampio Pharmaceuticals voluntarily delisted its common stock from the NYSE American, with the delisting expected to become effective around April 14, 2024. Following this, the company intended to suspend its reporting obligations by filing a Form 15 with the SEC around April 15, 2024. Trading now occurs on the OTC Markets, specifically listed as OTCMKTS with the ticker AMPE.

Here's a quick look at the physical and market presence data points:

The current Place reality for Ampio Pharmaceuticals, Inc. is defined by its corporate closure and the resulting lack of physical or commercial distribution channels:

• No active commercial sales force or distribution agreements in place.
• Corporate functions consolidated to an Englewood, Colorado office location.
• Stock trades on the over-the-counter market under ticker AMPE.
• The company is officially in dissolution status as of August 16, 2024.
• The primary development focus, OA-201, was terminated in February 2024.

If you're tracking assets, the primary physical location is the Englewood office, which supports minimal remaining administrative functions for the dissolution process.

Ampio Pharmaceuticals, Inc. (AMPE) - Marketing Mix: Promotion

You're looking at the promotion strategy for Ampio Pharmaceuticals, Inc. as of late 2025. Honestly, the promotion strategy has entirely shifted from product awareness to mandatory corporate disclosure, given the company's status.

The primary communication channel has been investor relations, specifically detailing the corporate wind-down and legal resolutions. This is not about selling a product; it's about managing the final obligations of the entity.

• The Plan of Dissolution was approved by stockholders on August 15, 2024.
• Ampio Pharmaceuticals, Inc. officially dissolved as of August 16, 2024.
• The intent is to distribute any remaining cash after settling legal obligations to stockholders, subject to Delaware Chancery Court approval.

A major step in reducing external communication was the filing of Form 15 with the SEC on or about April 15, 2024, to suspend reporting obligations under the Exchange Act. This action immediately ceased the requirement to file public reports such as Forms 10-K, 10-Q, and 8-K.

The focus for any remaining communication is strictly internal, centered on maximizing cash reserves to cover final liabilities, rather than external product marketing. The OA-201 development program was terminated after the pain reduction benefit was not observed in non-clinical studies. The company previously anticipated annualized cost savings of approximately $4.6 million from streamlined operations.

Recent public notices, which serve as the last vestiges of external promotion/disclosure, centered on legal settlements. These actions were necessary to close out past liabilities before final distribution.

The communication regarding these settlements was critical, as it directly impacted the final cash available for distribution to stockholders. For instance, the $3,000,000 settlement fund allocated 28% for attorneys' fees and up to $75,000 for Lead Counsel expenses.

The final public-facing activity is managing expectations around the remaining cash. As of the dissolution date, the company stated, 'At this point, we cannot forecast if cash will be available for distribution nor the timing of such a distribution.'

• Stock price on January 1st, 2025: $0.0052.
• Stock price increase from 52-week low: 100.00%.
• 52-week high: $0.16.
• Total Equity (Latest Reported): $4.21K.

Finance: draft final cash reconciliation statement for legal review by next Tuesday.

Ampio Pharmaceuticals, Inc. (AMPE) - Marketing Mix: Price

Ampio Pharmaceuticals, Inc. (AMPE) is operating in a pre-revenue stage, meaning there are no established commercial prices, discounts, or financing options for a product to set a customer-facing price policy.

The element of Price, in this context, is reflected entirely through the market's valuation of the company's equity, which indicates the perceived value of its pipeline and operational status.

The market capitalization for Ampio Pharmaceuticals, Inc. (AMPE) is extremely low, reported as approximately $5.9K as of November 26, 2025. This valuation reflects the wind-down status and lack of a viable commercial product pipeline.

The company has implemented significant cost-reduction measures to manage its burn rate:

• Staff cuts and subleasing facilities are saving about $4.6 million annually.
• The stock does not pay dividends; the dividend is $0.00 (0.00%).

The stock price data clearly reflects the market's assessment of the company's current financial standing and operational trajectory.

The stock price history shows extreme volatility and a significant decline from past valuations, underscoring the lack of a commercial price point for any product.

• Five years ago, the stock traded at a split-adjusted price of $17.50.
• The price has experienced a 99.97% decrease over the last five years.
• The stock recorded 12/30 (40%) green days over the last 30 days.